Foster ED, et al. - This study encompassed an examination of the health-related quality of life (HRQOL), functional health status, and health utility before and after pancreatic islet transplantation in CIT Consortium Protocol 07 (CIT-07) trial participants. Findings revealed that 87.5% of the subjects achieved the primary endpoint of freedom from severe hypoglycemic events (SHEs) along with glycemic control (HbA1c <7%; HbA1c <53 mmol/mol) at 1-year post–initial islet transplantation. Consistent, statistically significant, and clinically meaningful improvements were found among same subjects in condition-specific HRQOL and self-assessments of overall health.